(Q44635696)

4 December 2017

title

Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients (English)

1 reference

4 December 2017

Impact of Various Antiretroviral Drugs and Their Plasma Concentrations on Plasma Lipids in Heavily Pretreated HIV-Infected Patients (English)

1 reference

https://api.crossref.org/works/10.1310/8TXF-P814-8JPF-7TRY

26 March 2024

author name string

P. Clevenbergh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583849

26 March 2024

R. Garraffo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583849

26 March 2024

P. Dellamonica

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583849

26 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14583849

26 March 2024

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

http://www.tandfonline.com/doi/pdf/10.1310/8TXF-P814-8JPF-7TRY

1 reference

https://api.crossref.org/works/10.1310/8TXF-P814-8JPF-7TRY

26 March 2024

1 reference

4 December 2017

volume

4

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

330-336

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F8TXF-P814-8JPF-7TRY

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1310/8TXF-P814-8JPF-7TRY

26 March 2024

Identifiers

1 reference

4 December 2017

1 reference